Our mathematical model reproduces the overall dynamics of tumor progression and regression observed in a GEM model of pancreatic cancer treated with chemotherapies (cisplatin, paclitaxel, and gemcitabine) administered with or without stromal-targeting drugs (calcipotriol and losartan) and an immune checkpoint inhibitor (anti-PD-L1). This evidence concerns the gene CD274 and pancreatic neoplasm.